Comorbidity Indexing for Prediction of the Clinical Outcome After Stereotactic Body Radiation Therapy in Non-small Cell Lung Cancer

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2018 Nov 5

PMID 30390700

Citations 8

Authors

Julia Dreyer

Michael Bremer

Christoph Henkenberens

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine the prognostic impact of comorbidity and age in medically inoperable early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT) using the age-adjusted Charlson Comorbidity Index (aCCI).

Patients And Methods: Between November 2008 and January 2015, 196 consecutive patients with medically inoperable NSCLC were treated with SBRT at a single institution. The prescribed isocenter dose was either 60.0 Gray (Gy) in six fractions for central lung cancer or 56.25 Gy in three fractions for peripheral lung cancer. Baseline comorbidities were retrospectively retrieved according to available outclinic medical records as well as the hospital information system. The aCCI was scored for each patient and subjected according to outcome and toxicity as well as all of the single items of the aCCI and other clinical parameters using univariate and multivariate analysis.

Results: Thirty-one point 6 % (62/196) of patients were deceased, of whom 17.3% (34/196) died due to lung cancer and 14.3% (28/196) due to comorbidities. The median overall survival (OS) was 15.0 months (95% CI [11.9-18.1]), whereas the median cancer-specific survival (CSS) was not reached. An aCCI ≥7 compared with an aCCI ≤6 was significantly associated with an increased risk of death (HR 1.79, 95% CI [1.02-2.80], p = 0.04) and cancer-specific death (HR 9.26, 95% CI [4.83-24.39], p < 0.001), respectively. Neither OS nor CCS were significantly associated with age, sex, side (left vs. right), lobe, localization (central vs. peripheral), packyears, TNM, or any item of the aCCI. Considering the 14.3% (28/196) of deceased patients who died due to comorbidities, aCCI ≥9 was significantly associated with non-cancer-related death (HR 3.12, 95% CI [1.22-8.33], p = 0.02). The observed cumulative rate of radiation pneumonitis (RP) ≥2 was 12.7% (25/196). The aCCI had no statistical association with RP.

Conclusion: Advanced age and numerous comorbidities characterizing this patient population were successfully assessed using the aCCI in terms of survival. Therefore, we recommend that age and comorbidity be indexed using the aCCI as a simple scoring system for all patients treated with SBRT for lung cancer.

Citing Articles

Lung cancer, comorbidities, and medication: the infernal trio.

Pluchart H, Chanoine S, Moro-Sibilot D, Chouaid C, Frey G, Villa J Front Pharmacol. 2024; 14:1016976.

PMID: 38450055 PMC: 10916800. DOI: 10.3389/fphar.2023.1016976.

Considerations of Medical Preparedness to Assess and Treat Various Populations During a Radiation Public Health Emergency.

Winters T, Cassatt D, Harrison-Peters J, Hollingsworth B, Rios C, Satyamitra M Radiat Res. 2023; 199(3):301-318.

PMID: 36656560 PMC: 10120400. DOI: 10.1667/RADE-22-00148.1.

A comparison of mRNA and circRNA expression between squamous cell carcinoma and adenocarcinoma of the lungs.

Yu M, Tian Y, Wu M, Gao J, Wang Y, Liu F Genet Mol Biol. 2020; 43(4):e20200054.

PMID: 33196759 PMC: 7654371. DOI: 10.1590/1678-4685-GMB-2020-0054.

Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy.

Zeng X, Zhu S, Xu C, Wang Z, Su X, Zeng D Med Sci Monit. 2020; 26:e922576.

PMID: 32893263 PMC: 7496511. DOI: 10.12659/MSM.922576.

Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments.

Sun H, Wang H, Shi L, Wang M, Li J, Shi J BMJ Open. 2020; 10(2):e032336.

PMID: 32051302 PMC: 7045216. DOI: 10.1136/bmjopen-2019-032336.

References

Kirkhus L, Jordhoy M, Saltyte Benth J, Rostoft S, Selbaek G, Hjermstad M . Comparing comorbidity scales: Attending physician score versus the Cumulative Illness Rating Scale for Geriatrics. J Geriatr Oncol. 2016; 7(2):90-8. DOI: 10.1016/j.jgo.2015.12.003. View

Chang J, Senan S, Paul M, Mehran R, Louie A, Balter P . Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16(6):630-7. PMC: 4489408. DOI: 10.1016/S1470-2045(15)70168-3. View

Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U . Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2013; 190(1):26-33. PMC: 3889283. DOI: 10.1007/s00066-013-0450-y. View

Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M . Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004; 60(1):186-96. DOI: 10.1016/j.ijrobp.2004.02.060. View

Paix A, Noel G, Falcoz P, Levy P . Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiother Oncol. 2018; 128(3):534-540. DOI: 10.1016/j.radonc.2018.04.013. View

Baker R, Han G, Sarangkasiri S, DeMarco M, Turke C, Stevens C . Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys. 2012; 85(1):190-5. DOI: 10.1016/j.ijrobp.2012.03.041. View

Takeda A, Kunieda E, Ohashi T, Aoki Y, Oku Y, Enomoto T . Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest. 2011; 141(4):858-866. DOI: 10.1378/chest.11-1193. View

Extermann M, Overcash J, Lyman G, Parr J, Balducci L . Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16(4):1582-7. DOI: 10.1200/JCO.1998.16.4.1582. View

. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys. 1995; 31(5):1049-91. DOI: 10.1016/0360-3016(95)90159-0. View

10.

Kopek N, Paludan M, Petersen J, Hansen A, Grau C, Hoyer M . Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol. 2009; 93(3):402-7. DOI: 10.1016/j.radonc.2009.06.002. View

11.

Charlson M, Szatrowski T, Peterson J, Gold J . Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47(11):1245-51. DOI: 10.1016/0895-4356(94)90129-5. View

12.

Crabtree T, Denlinger C, Meyers B, El Naqa I, Zoole J, Krupnick A . Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010; 140(2):377-86. DOI: 10.1016/j.jtcvs.2009.12.054. View

13.

Palma D, Visser O, Lagerwaard F, Belderbos J, Slotman B, Senan S . Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol. 2011; 101(2):240-4. DOI: 10.1016/j.radonc.2011.06.029. View

14.

Raz D, Zell J, Ou S, Gandara D, Anton-Culver H, Jablons D . Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007; 132(1):193-9. DOI: 10.1378/chest.06-3096. View

15.

Nyman J, Johansson K, Hulten U . Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. Lung Cancer. 2005; 51(1):97-103. DOI: 10.1016/j.lungcan.2005.08.011. View

16.

Haque W, Verma V, Polamraju P, Farach A, Butler E, Teh B . Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer. Radiother Oncol. 2018; 129(2):264-269. DOI: 10.1016/j.radonc.2018.07.008. View

17.

Suissa S, DellAniello S, Ernst P . Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67(11):957-63. PMC: 3505864. DOI: 10.1136/thoraxjnl-2011-201518. View

18.

Mokhles S, Nuyttens J, Maat A, Birim O, Aerts J, Bogers A . Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis. Ann Surg Oncol. 2014; 22(1):316-23. DOI: 10.1245/s10434-014-3860-x. View

19.

Bryant A, Mundt R, Sandhu A, Urbanic J, Sharabi A, Gupta S . Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans. Ann Thorac Surg. 2017; 105(2):425-431. DOI: 10.1016/j.athoracsur.2017.07.048. View

20.

von Reibnitz D, Shaikh F, Wu A, Treharne G, Dick-Godfrey R, Foster A . Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC). Acta Oncol. 2018; 57(11):1567-1573. PMC: 6508090. DOI: 10.1080/0284186X.2018.1481292. View